- Home
- DXR vs TELA Comparison
DXR vs TELA Comparison
Compare DXR & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | TELA |
|---|---|---|
| Founded | 1970 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 50.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | DXR | TELA |
|---|---|---|
| Price | $14.25 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $25.00 | $3.31 |
| AVG Volume (30 Days) | 3.5K | ★ 105.6K |
| Earning Date | 02-27-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.46 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $66,306.00 | ★ $77,055,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | $37.92 | ★ N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $6.55 | $0.86 |
| 52 Week High | $14.76 | $3.08 |
Technical Indicators
Market Signals| Indicator | DXR | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 47.05 |
| Support Level | $13.20 | $1.08 |
| Resistance Level | $14.76 | $1.16 |
| Average True Range (ATR) | 0.59 | 0.06 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 86.45 | 47.77 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.